Comprehensive Study Guide to Cancer Biology: Cell Cycle Checkpoints, Apoptotic Cascades, Oncogenic Signaling, and Metabolic Reprogramming

Cell Division Fundamentals and Mitotic Checkpoints

• Four Universal Events of Cell Division:

  • Every dividing cell, regardless of organismal type, must complete four sequential events:
  • Initiation via a reproductive signal (external mitogenic cue or internal signal).
  • DNA replication to duplicate the entire genetic complement.
  • DNA segregation to apportion the replicated chromosomes equally into two daughter domains.
  • Cytokinesis, which constitutes the fourth and final event, physically separating the cytoplasm into two distinct daughter cells.
  • Mitosis versus Binary Fission:
  • Mitotic stages (prophase, metaphase, anaphase, telophase) are strictly restricted to eukaryotic cells.
  • Prokaryotic cells divide exclusively via binary fission and do not undergo mitosis, lacking anaphase, telophase, or mitotic spindle machinery.

• G1 Phase Regulation and the Restriction Point:

  • The restriction point represents a critical regulatory threshold located in late $G_1$.
  • Cells in $G_0$ or early $G_1$ strictly require mitogens and extracellular ligands to progress up to the restriction point.
  • Once a cell traverses the restriction point, external mitogens are no longer required to complete the division cycle.
  • The $G_1$ checkpoint is fundamentally governed by the Retinoblastoma protein ($Rb$).
  • Unphosphorylated $Rb$ binds to and suppresses the transcription factor $E2F$.
  • Cyclin $D$ forms functional heterodimeric complexes with Cyclin-Dependent Kinase $4$ ($CDK4$) and Cyclin-Dependent Kinase $6$ ($CDK6$).
  • The Cyclin $D$-$CDK4/6$ complexes phosphorylate $Rb$, converting it into an inactive, hyperphosphorylated state.
  • Hyperphosphorylation of $Rb$ relieves transcriptional inhibition on $E2F$, freeing $E2F$ to drive the transcription of genes necessary for entering $S$ phase, including Cyclin $E$.

• Cell Cycle Kinases and Cyclin Targeting:

  • $CDK$ Activation:
  • $CDK$-activating kinase ($CAK$) adds essential activating phosphate groups to activate $CDK$ complexes.
  • Wee1 kinase (referred to as "Want kinase") is an inhibitory kinase that adds inhibitory phosphates to $CDK$s, thereby preventing premature $CDK$ activation.
  • $CDK$ Inhibition Families:
  • The $p16$ family (INK4 inhibitors) specifically targets and inhibits $CDK4$ and $CDK6$.
  • The $p21$ family (CIP/KIP inhibitors) inhibits broader cyclin-$CDK$ complexes.
  • Therapeutic Rationale for Targeting $CDK$s over Cyclins:
  • In cancer therapeutics, $CDK$s are targeted preferentially over cyclins because $CDK$s are constitutively expressed throughout the cell cycle, whereas cyclins undergo periodic, cyclical synthesis and proteasome-mediated degradation.
  • It is far more pharmacologically feasible to target a constitutively present kinase than a transiently expressed cyclin.
  • Direct inhibition of $CDK$ catalytic activity renders upstream cyclin activity inconsequential, effectively arresting the cycle regardless of cyclin accumulation.

• G2 Checkpoint Machinery:

  • The $G_2$ DNA damage and progression checkpoint relies on the upstream sensor kinases $ATM$ and $ATR$.
  • The decatenation checkpoint operates at $G_2$ to ensure that entangled sister chromatids are fully disentangled prior to mitotic entry.

Apoptosis and Cell Death Mechanisms

• Comparison Between Apoptosis and Necrosis:

  • Morphological Changes:
  • Apoptotic cells undergo dramatic cell shrinkage and active membrane blebbing, followed by neat packaging into apoptotic bodies.
  • Necrotic cells experience osmotic dysregulation, leading to cellular swelling, organelle breakdown, and eventual plasma membrane rupture.
  • Immunological Response:
  • Apoptosis is an orderly, immunologically silent process; cellular fragments are phagocytosed without provoking an immune response.
  • Necrosis triggers a pronounced inflammatory response because the lysis of the plasma membrane releases intracellular contents into the extracellular space, signaling tissue trauma to the immune system.

• The Intrinsic (Mitochondrial) Apoptotic Pathway:

  • Activating Stimuli:
  • Triggered by intracellular stressors, primarily reactive oxygen species ($ROS$), oxidative stress, and extensive DNA damage.
  • Key Molecular Mediators:
  • Mitochondrial intermembrane space serves as a reservoir for apoptotic mediators, including Cytochrome $c$.
  • The $BCL-2$ protein family regulates mitochondrial outer membrane permeability, comprising both pro-apoptotic members (e.g., $BAX$, $BID$, $PUMA$/"coma") and anti-apoptotic members (e.g., $BCL-2$).
  • Pro-apoptotic $BID$ activates $BAX$, inducing $BAX$ oligomerization and insertion directly into the outer mitochondrial membrane to drive Mitochondrial Outer Membrane Permeabilization ($MOMP$).
  • Release of Cytochrome $c$ into the cytoplasm promotes the assembly of the apoptosome.
  • Initiator Caspase: Caspase-$9$ serves as the dedicated initiator caspase for the intrinsic pathway.

• The Extrinsic (Death Receptor) Apoptotic Pathway:

  • Activating Stimuli:
  • Initiated by extracellular death ligands (death factors) such as Tumor Necrosis Factor ($TNF$) and $Fas$ ligand ($FAS$).
  • Signaling Cascade:
  • Extracellular death ligands bind to corresponding transmembrane death receptors.
  • Adapter proteins such as $TRADD$ ("TRAD") and $FADD$ ("FAT") bind death receptors via their Death Domains ($DD$) and recruit downstream proteins via Death Effector Domains ($DED$).
  • This assembly forms the Death-Inducing Signaling Complex ($DISC$).
  • $BCL-2$ family members are not constituents of the $DISC$.
  • Initiator Caspase: Caspase-$8$ serves as the dedicated initiator caspase for the extrinsic pathway.
  • Pathway Cross-Talk:
  • The extrinsic pathway can cross-activate the intrinsic pathway via Caspase-$8$-mediated cleavage of $BID$ into truncated $BID$ ($tBID$), amplifying mitochondrial apoptotic signaling.

• Dual Regulatory Mechanisms of p53 in Apoptosis:

  • Transcription-Dependent Regulation:
  • Nuclear $p53$ functions as a transcription factor to upregulate the expression of pro-apoptotic $BCL-2$ family genes, specifically $PUMA$ ("coma").
  • Non-Transcriptional (Cytoplasmic) Regulation:
  • Cytoplasmic $p53$ directly interacts with and activates the pro-apoptotic effector protein $BAX$, stimulating outer mitochondrial membrane permeabilization independent of gene transcription.

• Definition of Autophagy:

  • Autophagy is a catabolic cellular process characterized by "eating one's self," sequestering damaged organelles and cytoplasmic components into double-membrane autophagosomes for lysosomal degradation.

Oncogenes, Tumor Suppressors, and Intracellular Signaling Cascades

• Functional Classifications of Cancer Genes:

  • Loss-of-Function Mutations:
  • Result in a complete cessation of gene product activity, exemplified by loss-of-function mutations in the tumor suppressor $p53$.
  • Gain-of-Function Mutations:
  • Impart an altered, elevated, or novel biochemical activity onto the encoded protein.
  • Expression Profiles in Neoplasia:
  • Oncogenes are overexpressed or hyperactivated during malignant transformation.
  • Tumor suppressor genes are underexpressed or inactivated during malignant transformation.
  • A point mutation located in a non-coding regulatory promoter or enhancer sequence of a proto-oncogene converts it into an oncogene via transcriptional overexpression rather than underexpression.

• Tumor Suppressor Definitions and Knudson's Two-Hit Hypothesis:

  • Definition of a Tumor Suppressor Gene:
  • A gene that encodes proteins that actively inhibit cell cycle progression, promote cellular differentiation, induce apoptosis, or participate in double-strand DNA repair.
  • True tumor suppressor genes must be linked to a recognized hereditary cancer predisposition syndrome.
  • Knudson's Two-Hit Hypothesis:
  • Tumor suppressor genes operate in a genetically recessive manner at the cellular level.
  • Inactivation requires two distinct mutational "hits" (inactivation of both functional alleles), in sharp contrast to oncogenes, which act in a dominant fashion requiring an activating mutation in only a single allele.

• Cancer Predisposition Syndromes:

  • Li-Fraumeni Syndrome (transcribed phonetically as "Lee Brownian syndrome"):
  • A familial cancer predisposition syndrome caused by an inherited germline mutation in the tumor suppressor $p53$.
  • Familial Breast and Ovarian Cancer Syndrome:
  • Caused by inherited germline mutations in $BRCA1$ and $BRCA2$.
  • Cellular Mechanism: $BRCA1$ and $BRCA2$ are essential mediators of the homologous recombination repair pathway, which resolves double-strand DNA breaks.
  • Absence of functional $BRCA1/2$ leaves double-strand breaks unrepaired, causing genomic instability, chromosomal rearrangements, and malignant persistence.
  • Epidemiological Distribution: Less than $10\%$ of all diagnosed breast cancers are familial (arising from inherited germline mutations); approximately $90\%$ of breast cancers arise via sporadic somatic mutations.

• The PTEN and PI3K/AKT Signaling Axis:

  • $PTEN$ is a lipid and protein phosphatase that functions as a critical tumor suppressor.
  • Phosphoinositide 3-kinase ($PI3K$) phosphorylates phosphatidylinositol 4,5-bisphosphate ($\text{PIP}_2$) to generate phosphatidylinositol 3,4,5-trisphosphate ($\text{PIP}_3$).
  • $PTEN$ directly antagonizes $PI3K$ by removing the $3^{\prime}$-phosphate from $\text{PIP}_3$, converting it back to $\text{PIP}_2$.
  • Reintroducing a functional $PTEN$ allele into a $PTEN$-deficient cancer cell line decreases intracellular $\text{PIP}_3$ levels and subsequently reduces the activation of downstream kinase $AKT$.

• Chronic Myelogenous Leukemia (CML) and Targeted Therapy Selection:

  • In a $CML$ tumor harboring a small subpopulation with a $BCR-ABL$ mutation that confers reduced sensitivity to the tyrosine kinase inhibitor Gleevec ($\text{GLEBEC}$), prolonged drug exposure acts as an evolutionary filter.
  • The treatment selectively eliminates Gleevec-sensitive cells while sparing the mutant resistant cells, resulting in clonal expansion and dominance of the drug-resistant subpopulation.

• Epidermal Growth Factor Receptor (EGFR) Dynamics and Herceptin:

  • Termination Mechanisms:
  • Normal termination of receptor tyrosine kinase signaling by $EGFR$ requires ligand-induced receptor endocytosis followed by lysosomal degradation.
  • Failure of endocytic internalization leaves active $EGFR$ on the plasma membrane, resulting in persistent downstream signaling.
  • Truncated receptor variants lacking the extracellular ligand-binding domain undergo constitutive activation, firing continuously in the total absence of ligand.
  • Herceptin ($\text{trastuzumab}$):
  • A humanized monoclonal antibody designed to bind the extracellular domain of the $HER2$/$EGFR$-family receptor, sterically blocking ligand interactions and dampening downstream proliferative signaling cascades.

• The RAS-RAF-MEK-MAPK Signaling Cascade:

  • Activation by Guanine Nucleotide Exchange Factors ($GEF$s):
  • The son-of-sevenless ($SOS$) protein functions as a $GEF$ for the small GTPase $RAS$.
  • $SOS$ is not a kinase; it does not phosphorylate $GDP$.
  • Instead, $SOS$ induces the dissociation of $GDP$ from $RAS$, allowing the far more abundant intracellular $GTP$ to bind.
  • Inactivation by GTPase-Activating Proteins ($GAP$s):
  • Active $RAS$-$GTP$ is inactivated when $GAP$s stimulate the intrinsic GTPase activity of $RAS$, accelerating the hydrolysis of bound $GTP$ to $GDP$.
  • Downstream Phosphorylation Cascade:
  • Bound $GTP$ induces a critical conformational shape change in $RAS$, allowing it to recruit and bind $RAF$.
  • $RAS$ is not a kinase and does not phosphorylate $RAF$.
  • $RAF$ is a serine/threonine kinase that phosphorylates and activates $MEK$.
  • Activated $MEK$ is a kinase that phosphorylates and activates $MAP$ kinase ($MAPK$).
  • $RAF$, $MEK$, and $MAP$ kinase form an intracellular serine/threonine kinase signaling relay.
  • Active $MAP$ kinase translocates from the cytoplasm directly into the nucleus.
  • In the nucleus, $MAP$ kinase phosphorylates specific transcription factors (modulating their activity via phosphorylation, not via ubiquitin ligase-mediated ubiquitination) to induce transcription of genes that promote cell cycle entry.

• Aneuploidy and Extrachromosomal DNA:

  • Aneuploidy:
  • An abnormal, unbalanced chromosomal number arising from chromosomal missegregation during cell division.
  • Contributes to tumorigenesis by disrupting gene dosage, causing the catastrophic overexpression of oncogenes or loss of tumor suppressor loci.
  • Extrachromosomal DNA ($\text{ecDNA}$):
  • Amplified oncogenes frequently reside outside of nuclear chromosomes on extrachromosomal DNA elements.
  • $\text{ecDNA}$ is packaged in an open, substantially less compact chromatin structure than genomic chromosomes, rendering amplified oncogenes exceptionally accessible to transcriptional machinery.
  • Mutational Types:
  • Nonsense mutations convert an amino acid-specifying codon into a premature stop codon, yielding truncated, non-functional proteins.
  • Missense mutations alter a codon to specify a different amino acid, changing the primary structure of the protein.

Hallmarks of Cancer and Metabolic Reprogramming

• Established Biological Hallmarks of Cancer:

  • Growth Signal Autonomy (e.g., constitutive $EGFR$ and downstream signaling independent of external growth factor stimulation).
  • Evasion of Growth Inhibitory Signals (e.g., loss of $Rb$, bypassing checkpoints).
  • Evasion of Programmed Cell Death (e.g., suppression of apoptosis via $BCL-2$ overexpression or $p53$ mutation).
  • Limitless Replicative Potential (e.g., activation of telomerase or alternative lengthening of telomeres preventing replicative senescence).
  • Genome Instability and Mutation (the foundational enabling hallmark driving tumor evolution).
  • Angiogenesis, Invasion, and Metastasis (programs facilitating neovascularization and physical dissemination).
  • Emerging Hallmarks for Future Study: Avoiding immune destruction and tumor-promoting inflammation.

• Reprogramming Cellular Energy Metabolism:

  • Normal Respiration Efficiency:
  • Differentiated cells in the presence of oxygen prefer complete cellular respiration, routing glucose through glycolysis, the citric acid cycle, and oxidative phosphorylation to produce $32\,\text{ATP}$ per single molecule of glucose.
  • Under anaerobic conditions (oxygen deprivation), normal cells switch to lactic acid fermentation, yielding only $2\,\text{ATP}$ per molecule of glucose.
  • Neoplastic Metabolic Rewiring (The Warburg Effect):
  • Cancer cells reprogram their core metabolic pathways to undergo aerobic glycolysis (fermentation in the presence of oxygen).
  • Although producing only $2\,\text{ATP}$ per glucose is energetically inefficient, cancer cells dramatically upregulate glucose import, rapidly consuming high volumes of glucose to generate $ATP$ and metabolic intermediates needed for rapid biomass accumulation.

• Cancer Stem Cells and Embryonic Program Reactivation:

  • Cancer stem cells do not constitute a formal hallmark of cancer, but are intimately tied to tumorigenesis, recurrence, and metastasis.
  • Characteristics shared with normal stem cells include indefinite self-renewal and migratory capability.
  • During normal embryonic development, cells actively migrate to establish organ systems, after which migratory and developmental programs are transcriptionally silenced.
  • Neoplastic cells reactivate these dormant embryonic developmental pathways to facilitate tissue invasion and metastatic seeding.

Cancer Stem Cells and Developmental Differentiation

• Homeostatic Regulation of Cell Numbers:

  • In normal tissues, total cell number is strictly maintained by an equilibrium across three processes:
  • Cell proliferation (cell division), which increases cell number.
  • Programmed cell death (apoptosis), which decreases cell number.
  • Differentiation, which transitions dividing stem or progenitor cells into a terminally differentiated state where proliferation permanently ceases.

• Models of Cancer Stem Cell Dynamics:

  • Hierarchical Cancer Stem Cell Model:
  • A dedicated, self-renewing cancer stem cell subpopulation resides within the tumor, continuously dividing to regenerate the stem pool while generating differentiated progeny that constitute the tumor bulk.
  • Stochastic / Dedifferentiation Model:
  • Mature, differentiated tumor cells retain phenotypic plasticity, re-entering a stem cell-like state through the reactivation of stemness programs, thereby acquiring self-renewal capacity even after reaching terminal differentiation.

• Tumor Suppressors in Differentiation:

  • In addition to halting cell cycle progression (e.g., $Rb$) and orchestrating apoptosis or DNA repair, tumor suppressors drive cells toward terminal differentiation, permanently removing them from the proliferative pool.

• Developmental Biology and Fate Maps:

  • Fate maps visually track embryonic development from the earliest cleavages through the formation of the three primary germ layers:
  • Ectoderm.
  • Mesoderm.
  • Endoderm.
  • Fate maps delineate the developmental trajectories of specific cellular lineages, identifying precise developmental stages where stem cell populations can be isolated and showing how lineage programs become corrupted during oncogenesis.

Course Logistics and Examination Breakdown

• Examination Grading and Point Distribution:

  • Question 33 (Total $4$ points):
  • Part A ($3$ points total):
    • Point $1$: Explaining the involvement of Cyclin $D$ in advancing the cell cycle from $G_1$ into $S$ phase.
    • Point $2$: Documenting the physical interaction of Cyclin $D$ with $CDK4$ and $CDK6$, resulting in kinase activation.
    • Point $3$: Identifying downstream targets regulated by this complex, specifically activating $E2F$ activity and modulating Cyclin $E$ expression.
  • Part B ($1$ point):
    • Detailing why cancer therapies preferentially target constitutively expressed $CDK$s over cyclically fluctuating cyclins.
  • Question 34 (Total $6$ points):
  • Part A ($4$ points total):
    • Point $1$: Contrasting the initiating stimuli of the intrinsic pathway (intracellular stressors like reactive oxygen species and DNA damage) versus the extrinsic pathway (extracellular death factors like $TNF$ and $FAS$).
    • Points $2$ and $3$: Identifying major component proteins in the intrinsic pathway (Cytochrome $c$, $BCL-2$ family members) versus the extrinsic pathway ($TNF$, $Fas$, $TRADD$, $FADD$).
    • Point $4$: Distinguishing initiator caspases: Caspase-$9$ for the intrinsic pathway and Caspase-$8$ for the extrinsic pathway.
  • Part B ($2$ points total):
    • Describing the dual roles of $p53$ in apoptosis: transcription-dependent upregulation of pro-apoptotic targets ($PUMA$/"coma") and transcription-independent, direct cytoplasmic activation of $BAX$.
  • Question 35:
  • Knudson's Two-Hit Hypothesis ($1$ point):
    • Detailing that both alleles of a tumor suppressor must be inactivated due to their genetically recessive behavior, unlike single-allele dominant oncogenes.
  • Tumor Suppressor Definition ($2$ points):
    • Coding for proteins that arrest the cell cycle or trigger apoptosis, and possessing an associated hereditary cancer predisposition syndrome.
  • BRCA Syndrome and Mechanism ($2$ points):
    • Identifying Familial Breast and Ovarian Cancer Syndrome and explaining that defects in homologous recombination lead to unrepaired double-strand DNA breaks.
  • Sporadic versus Familial Proportions ($1$ point):
    • Documenting that less than $10\%$ of breast cancers originate from inherited germline mutations, with $90\%$ arising sporadically.
  • RAS Pathway Cascade ($4$ points):
    • Describing that $SOS$ acts as a $GEF$ facilitating $GTP$ exchange on $RAS$ without kinase activity; active $RAS$-$GTP$ induces a conformational shift to activate $RAF$; $RAF$ phosphorylates $MEK$; active $MEK$ phosphorylates $MAP$ kinase; and active $MAP$ kinase enters the nucleus to phosphorylate transcription factors.

• Upcoming Student Presentation Guidelines:

  • Presentation Topic Categories:
  • Technology employed in basic cancer research.
  • Diagnostic technology utilized in cancer detection.
  • Preventative cancer technology.
  • Group Sizing and Evaluation Policy:
  • Students may choose to present individually or in pairs (maximum of $2$ students per group).
  • Group partners receive the identical grade regardless of individual workload distribution.
  • Scheduling:
  • Presentations will occur predominantly during dead week, with slots opening during the week immediately prior.

• Developmental Biology Worksheet Assignment:

  • Topic: Embryology, fate maps, and the three germ layers.
  • Submission Deadline: Monday at $5:00\,\text{PM}$.
  • Question $4$ Grading Policy: Graded leniently on demonstrated effort rather than strict correctness due to technical complexity.